Price defends HHS budget cuts, vows 'to uphold the law' of ACA

| | Health Exec | Policy & Regulations

HHS Secretary Tom Price, MD, faced a barrage of questions from Democrats about his plans for the Affordable Care Act (ACA) at a House Appropriations Committee hearing.

The meeting was the first chance lawmakers have had to question Price after the White House shelved the American Health Care Act, the Republican and President Donald Trump's plan to repeal and replace the ACA. Pressed on subjects including budget cuts and his support for the ACA, the Georgia physician remained relatively vague in his answers.

He did, at one point, say HHS would support the ACA for the foreseeable future.

"So long as the law is on the books, we at the department are obliged to uphold the law," Price said.

Click the link below for more information:

Democrats Ask HHS Chief: Do You Plan to Sabotage Obamacare?

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.